• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Boston Scientific’s Vici venous stent meets primary endpoints at 1 year

Boston Scientific’s Vici venous stent meets primary endpoints at 1 year

January 22, 2019 By Sarah Faulkner

Boston ScientificBoston Scientific (NYSE:BSX) today touted 12-month data for its Vici venous stent in people with significant obstructions in the illiofemoral venous outflow tract.

Researchers reported that the Vici stent met its primary efficacy endpoint with a primary patency rate of 84% at one year. Nearly 99% of people treated with the Vici stent were free from major adverse events at 30 days, Boston Scientific noted.

“In treating patients with venous obstruction, the primary goal is to restore and maintain vessel patency to ensure the return of blood flow to the heart,” principal investigator Dr. Mahmood Razavi said in prepared remarks. “In these results, the Vici stent demonstrated excellent performance outcomes in a difficult-to-treat patient population, which translates to improvement of long-term symptoms and enhanced quality of life in these patients.”

The results of the 170-patient trial will be used to support FDA approval for Vici, according to the president of Boston Scientific’s peripheral interventions unit, Jeff Mirviss.

“This trial is unique in the fact that it studied a very challenging patient population,” he added. “Three quarters of the patients in this trial have chronic venous disease, which is a debilitating condition that patients suffer from pain and swelling and ulceration. It’s the toughest of the toughest of venous diseases. And the Vici stent performed extremely well in this difficult patient population.

“Our view is that this’ll be an important treatment alternative for physicians that are treating venous disease. There are no on-label venous stents in the US. And so physicians are using arterial stents off-label, and I think this will give them a really high quality, safe and effective choice to treat their patients with,” Mirviss said.

The Boston Scientific executive noted that the Vici venous stent perfomed well, in part, due to its unique design.

“The Vici venous stent was purposely built for the venous anatomy, and the venous system is very different than the arterial system. It’s important for stents to have a lot of strength and flexibility and resistance to crushing. And the lumen shape matters a lot, – what you get with the Vici stent is a very nice round, circular lumen and that circular lumen is important for blood flow and overall performance,” he said. “And so in addition to being on-label and excellent clinical data, that design intent is a critical success factor.”

Filed Under: Clinical Trials, Featured, Regulatory/Compliance, Vascular, Wall Street Beat Tagged With: Boston Scientific

More recent news

  • Medtronic partners with IRCAD on Hugo, Affera surgical training
  • 23andMe co-founder wins bid to take back control of company
  • Neurent Medical opens new manufacturing facility in Ireland
  • Brain Navi wins FDA nod for neurosurgical robot
  • Adona Medical completes enrollment in first-in-human interatrial shunt trial

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy